772 Wearable Cardiac Technologies for Older Adults, Clinician Perspectives on the Design and Application by Ferguson, C et al.
at Hospital 2). Statistical analysis was performed using the
Pearson Chi-Square test.
Results: Mobile phone ownership data was available for
427 patients (90.5%). The mean age was 71.5 years. In pa-
tients under the age of 60, the smartphone ownership rate
was 90% (81/90). In the patients aged 60-69, the rate was
83.1% (69/83), which was not significantly different to those
under the age of 60 (p=0.19). In patients aged 70-79, the rate
of smartphone ownership fell to 53.3% (57/107), and was
even lower in patients aged 80 and above (23.8%, 35/112). P
value for significance overall was ,0.001.
Conclusions: 87% percent of inpatients under the age of 70
owned smartphones, and this represents a population that
could be targeted by mHealth innovations. Smartphone-
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Background: New devices offer promise in the detection
of arrhythmia and monitoring cardiac health status amongst
other clinically useful parameters. However, the clinical
utility and usability from the perspectives of clinicians is
largely unexplored.
Objective: This study aimed to explore clinician perspec-
tives on the use of wearable cardiac monitoring technology
for older adults.
Methods: Descriptive qualitative study using semi-struc-
tured focus group interviews. Clinicians were recruited
through purposive sampling of physicians, nurses and allied
health staff working in three tertiary level hospitals.
Verbatim transcripts were analysed using thematic content
analysis to identify themes.
Results: Clinicians representing physicians, nurses and
allied health staff working in three tertiary level hospitals
completed four focus group interviews between May 2019
and July 2019. There were 50 participants, 28 men and 22
women including cardiologists, geriatricians, nurses, and
allied health. The focus groups generated three overarching,
interrelated themes:
i) The current state of play, understanding the perceived
challenges of patient cardiac monitoring in hospitals
ii) Priorities in cardiac monitoring, what parameters should
new technologies measure?
iii) Cardiac monitoring of the future, ‘the ideal device’.
Conclusion: There remain pitfalls related to the design of
wearable cardiac technology for older adults which present
clinical challenges. These pitfalls and challenges likely
negatively impact uptake of wearable cardiac monitoring in
routine clinical care. Partnering with clinicians and patients
in the co-design of new wearable cardiac monitoring tech-
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Background: Real-world data comparing outcomes for
prasugrel, ticagrelor and clopidogrel use in patients under-
going percutaneous coronary intervention (PCI) is lacking.
Methods: Patients discharged following PCI and receiving
dual anti-platelet therapy were stratified by thienopyridine
received. We assessed the association of thienopyridine type
with 1 and 2-year MACE (death, MI, stroke) adjusted for
baseline clinical/lesion characteristics using data collected
prospectively from 14 Australian sites. Secondary endpoints
included safety, specifically the incidence of major bleeding
(BARC 3,4 or 5) at discharge.
Results: Data were available for 12,940 procedures from
November 2008 until March 2019. Patients receiving prasu-
grel were more likely to be male, younger (mean age
Outcome % Prasugrel Ticagrelor Clopidogrel p
N 692 2968 9280
Major bleeding % 0.1 0.2 0.4 0.21
MACE 2-year (n) % (21) 0.03 (120) 0.04 (446) 0.05 0.03
MACE 2-year n/
1000 patient-years
1.8 2.8 2.7 0.03
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